These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 37855457)
1. The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis. Kim KA; Kim NJ; Choo EH Eur J Prev Cardiol; 2024 Feb; 31(3):291-301. PubMed ID: 37855457 [TBL] [Abstract][Full Text] [Related]
2. Fibrates for secondary prevention of cardiovascular disease and stroke. Wang D; Liu B; Tao W; Hao Z; Liu M Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD009580. PubMed ID: 26497361 [TBL] [Abstract][Full Text] [Related]
3. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Marston NA; Giugliano RP; Im K; Silverman MG; O'Donoghue ML; Wiviott SD; Ference BA; Sabatine MS Circulation; 2019 Oct; 140(16):1308-1317. PubMed ID: 31530008 [TBL] [Abstract][Full Text] [Related]
4. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766 [TBL] [Abstract][Full Text] [Related]
5. Effects of fibrates in kidney disease: a systematic review and meta-analysis. Jun M; Zhu B; Tonelli M; Jardine MJ; Patel A; Neal B; Liyanage T; Keech A; Cass A; Perkovic V J Am Coll Cardiol; 2012 Nov; 60(20):2061-71. PubMed ID: 23083786 [TBL] [Abstract][Full Text] [Related]
6. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. Silverman MG; Ference BA; Im K; Wiviott SD; Giugliano RP; Grundy SM; Braunwald E; Sabatine MS JAMA; 2016 Sep; 316(12):1289-97. PubMed ID: 27673306 [TBL] [Abstract][Full Text] [Related]
8. Benefits and harms of fibrate therapy in patients with type 2 diabetes: a systematic review and meta-analysis. Rodriguez-Gutierrez R; Garcia-Leal M; Raygoza-Cortez K; Flores-Rodríguez A; Moreno-Alvarado M; Heredia-Martínez EM; Vazquez-Baquerizo B; Guerra-Espiricueta R; Muñoz-Silva V; Gonzalez-Gonzalez JG Endocrine; 2023 Aug; 81(2):231-245. PubMed ID: 37247046 [TBL] [Abstract][Full Text] [Related]
9. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis. Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686 [TBL] [Abstract][Full Text] [Related]
10. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599 [TBL] [Abstract][Full Text] [Related]
11. Under-representation of ethnic and regional minorities in lipid-lowering randomized clinical trials: a systematic review and meta-analysis. Sawant S; Wang N Eur J Prev Cardiol; 2023 Aug; 30(11):1120-1131. PubMed ID: 36748994 [TBL] [Abstract][Full Text] [Related]
12. Fibrates for primary prevention of cardiovascular disease events. Jakob T; Nordmann AJ; Schandelmaier S; Ferreira-González I; Briel M Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009753. PubMed ID: 27849333 [TBL] [Abstract][Full Text] [Related]
13. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. Navarese EP; Robinson JG; Kowalewski M; Kolodziejczak M; Andreotti F; Bliden K; Tantry U; Kubica J; Raggi P; Gurbel PA JAMA; 2018 Apr; 319(15):1566-1579. PubMed ID: 29677301 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. Khan SU; Khan MU; Virani SS; Khan MS; Khan MZ; Rashid M; Kalra A; Alkhouli M; Blaha MJ; Blumenthal RS; Michos ED Eur J Prev Cardiol; 2022 Feb; 28(18):2001-2009. PubMed ID: 33624058 [TBL] [Abstract][Full Text] [Related]
16. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis. Choi HD; Shin WG; Lee JY; Kang BC Vascul Pharmacol; 2015; 65-66():23-30. PubMed ID: 25451563 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316 [TBL] [Abstract][Full Text] [Related]
19. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up. Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645 [TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Robinson JG; Wang S; Jacobson TA Am J Cardiol; 2012 Nov; 110(10):1468-76. PubMed ID: 22906895 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]